Depressive Symptom Dimensions in Treatment-Resistant Major Depression and Their Modulation With Electroconvulsive Therapy.
Adult
Aged
Aged, 80 and over
Antidepressive Agents
/ therapeutic use
Benzodiazepines
/ therapeutic use
Combined Modality Therapy
Depressive Disorder, Major
/ psychology
Depressive Disorder, Treatment-Resistant
/ psychology
Electroconvulsive Therapy
/ methods
Factor Analysis, Statistical
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Psychiatric Status Rating Scales
Treatment Outcome
Journal
The journal of ECT
ISSN: 1533-4112
Titre abrégé: J ECT
Pays: United States
ID NLM: 9808943
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
pubmed:
30
8
2019
medline:
28
5
2021
entrez:
30
8
2019
Statut:
ppublish
Résumé
Symptom heterogeneity in major depressive disorder obscures diagnostic and treatment-responsive biomarker identification. Whether symptom constellations are differentially changed by electroconvulsive therapy (ECT) remains unknown. We investigate the clustering of depressive symptoms over the ECT index and whether ECT differentially influences symptom clusters. The 17-item Hamilton Depression Rating Scale (HDRS-17) was collected from 111 patients with current depressive episode before and after ECT from 4 independent participating sites of the Global ECT-MRI Research Collaboration. Exploratory factor analysis of HDRS-17 items pre- and post-ECT treatment identified depressive symptom dimensions before and after ECT. A 2-way analysis of covariance was used to determine whether baseline symptom clusters were differentially changed by ECT between treatment remitters (defined as patients with posttreatment HDRS-17 total score ≤8) and nonremitters while controlling for pulse width, titration method, concurrent antidepressant treatment, use of benzodiazepine, and demographic variables. A 3-factor solution grouped pretreatment HDRS-17 items into core mood/anhedonia, somatic, and insomnia dimensions. A 2-factor solution best described the symptoms at posttreatment despite poorer separation of items. Among remitters, core mood/anhedonia symptoms were significantly more reduced than somatic and insomnia dimensions. No differences in symptom dimension trajectories were observed among nonremitting patients. Electroconvulsive therapy targets the underlying source of depressive symptomatology and may confer differential degrees of improvement in certain core depressive symptoms. Our findings of differential trajectories of symptom clusters over the ECT index might help related predictive biomarker studies to refine their approaches by identifying predictors of change along each latent symptom dimension.
Identifiants
pubmed: 31464814
doi: 10.1097/YCT.0000000000000623
pmc: PMC7044066
mid: NIHMS1534476
pii: 00124509-202006000-00010
doi:
Substances chimiques
Antidepressive Agents
0
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-129Subventions
Organisme : NIMH NIH HHS
ID : K24 MH102743
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103472
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH092301
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH110008
Pays : United States
Références
Curr Psychiatry Rep. 2008 Dec;10(6):465-73
pubmed: 18980729
Proc IEEE Int Symp Biomed Imaging. 2017 Apr;2017:502-506
pubmed: 30713592
Eur Arch Psychiatry Clin Neurosci. 2001;251 Suppl 2:II6-12
pubmed: 11824839
Neuropsychopharmacology. 2018 Apr;43(5):1078-1087
pubmed: 28758644
Int J Methods Psychiatr Res. 2011 Dec;20(4):e69-82
pubmed: 22057975
Nat Med. 2017 Jan;23(1):28-38
pubmed: 27918562
Psychiatry Res. 2003 May 1;118(1):39-45
pubmed: 12759160
Arch Gen Psychiatry. 2000 May;57(5):425-34
pubmed: 10807482
Neuropsychopharmacology. 2016 Sep;41(10):2481-91
pubmed: 27067127
Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jan;1(1):77-86
pubmed: 26878070
Psychol Med. 2019 May;49(7):1118-1127
pubmed: 29962359
World Psychiatry. 2015 Oct;14(3):309-10
pubmed: 26407785
Neuroimage Clin. 2017 Feb 14;14:422-432
pubmed: 28275543
Psychiatry Res. 2008 Oct 30;161(1):116-20
pubmed: 18755514
Psychopharmacology (Berl). 2002 Aug;163(1):20-5
pubmed: 12185396
Schizophr Res. 1996 May;19(2-3):205-12
pubmed: 8789919
Br J Psychiatry. 1992 Feb;160:206-11
pubmed: 1540760
Neuropsychopharmacology. 2009 Jul;34(8):2002-10
pubmed: 19225453
Am J Psychiatry. 2004 Dec;161(12):2163-77
pubmed: 15569884
Annu Rev Public Health. 2013;34:119-38
pubmed: 23514317
BMC Med. 2012 Dec 04;10:156
pubmed: 23210727
J Psychiatr Res. 1993 Jul-Sep;27(3):259-73
pubmed: 8295158
Acta Psychiatr Scand. 1995 Sep;92(3):168-72
pubmed: 7484192
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
J ECT. 2010 Jun;26(2):87-90
pubmed: 19710622
J Psychiatr Res. 2002 Nov-Dec;36(6):437-48
pubmed: 12393314
Acta Psychiatr Scand. 1981 Mar;63(3):290-9
pubmed: 7015793
J Consult Clin Psychol. 1986 Feb;54(1):54-9
pubmed: 3958302
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
Depress Anxiety. 2005;21(2):95-7
pubmed: 15884092
CBE Life Sci Educ. 2016 Winter;15(4):
pubmed: 27856555
Mol Psychiatry. 2015 May;20(5):609-14
pubmed: 25092248
Acta Psychiatr Scand. 1997 Dec;96(6):416-23
pubmed: 9421337
Br J Clin Psychol. 1984 May;23 ( Pt 2):93-9
pubmed: 6722384
Psychol Med. 2017 Feb;47(3):518-530
pubmed: 27780482
Prim Care Companion J Clin Psychiatry. 2005;7(4):167-76
pubmed: 16163400
Compr Psychiatry. 2001 Mar-Apr;42(2):161-5
pubmed: 11244153
J Affect Disord. 2016 Jan 15;190:842-845
pubmed: 25487682
J Psychiatr Res. 2000 Jan-Feb;34(1):3-10
pubmed: 10696827
J ECT. 2004 Mar;20(1):13-20
pubmed: 15087991
J Psychiatr Res. 2008 Oct;42(12):1000-9
pubmed: 18206909